Mediti Pharma's Unattributed VC Round

Mediti Pharma raised a round of funding on June 20, 2016. Investors include TVM Capital Life Science.

Mediti Pharma is developing a compound, MP-101, originally discovered by Eli Lilly and Company for the treatment of Alzheimer's disease (AD) psychosis. …

Articles about Mediti Pharma's Unattributed VC Round: